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Figure 1 Antimicrobial activity and 13-laetamase srability of oral
cephalosporins
fr 111 lack of c mpli, nce. Therefore. for example, in tonsillo-
pharyngitis, penicillin fuilurcs ,ppcar to occur nm bec. use of
Ie isrant Group A ~ hemolytic mept cocci (GA ) (no resistant
strain.1 have been dctected worldwide so fur), but because of the
presence 0 ~-1aC(( Illa e-producing copathogens that may
de. troy lactam-nng antibiotics and, as Brook 111 ha noted.
'shield' trept COCCI frOIl1 the a Ii n of penicilJjn.
$rudie h, ve implicated aerobcs uch IllphyJor(J(llIs IImeltS
and anaerobes such as Borleroides pp. in this role. Pellicillin
failures in tonsiLlopharyngitis arc III orne pbces up abolll 30%,
even though mains 0 GAS rCOlam susceptible to penicillin in
vitro. In several studies It could be shown that. moxicillin/
c1avulanatc is able to eradicate GA (rolll the upper respiratoty
tract of patients in whom preVIous tre.1tlllc.nt w1th oral penicillin
V f.liled [2]. Also, the role of oral ceph: losporins as first-line
drugs for treating pharyngitis may broaden. 'nce Dille of thi.~
c1a.~ (especially tho e of third generation) are highly resi tant to
several types of j3-laCtMll; e. R.ecent comparative trials show
that third-generation cephaJosporins arc superior to penicillin in
eradicating GAS, and equivalent to penicillin cliruc:illy, whereas
it is sufficient to treat the patient willi a 5-cl.1Y administration
compared with a IO-day penicillin V treatment. The efficacy of
such a 5-day course with econd-, nd third-generation
ceph, losponns had been delllol1,ltrated in different studics 13,4].
In recent years, S. prltlllllO"inf resisClnt to penicillins and
other antibiotics have been appearing with disturbing
frequency [5-7). In maoy places, however, the detecClble
At the beginning of the development of orally adminm:rnble
cephal sporillS th~"Se dnlgs generally Ihared the antib;ICterial
speCtra of the parenteral first-generation agents, albeit with a
MlmelVh;lt lower degree of:lctlVity. But with the development of
second-and third-generation parenteral cephalosporins. new oral
dcnvJtlvcs wtth simi!. r or lame specmllTI of activity were also
laullchcd. efuroxinlt: axenl, for example, LI an ester, prodrug of
celUroXlme WIth exactly the s,11l1e antimicrobial activity as
cefur x.ime i elf. Following oral administration, the prodnlg is
well absorbed from the ~Itrointestin.'li traCt and de-esterified by
nonspecific CSlCrases to cefuroxime. In different countries tht're arc
S<.'Veral othcr esters of formerly only i.v.-administrablc cephaJo-
sponm on the market, such as cefotiam-hexetil or cefpodoxlJllC-
proxecil and cefCLlmet-plvoxyl. The latter two rc rcprl"Sentativcs
of the tim generao n. L racarbef, cefucimc, ccftibutcn and
cefdinir are aIso \videly wcd oral cephaJ sporins in pedi.ltrics and
auul . For pr cribing for children m, ny dLfferenc Ii rlllulations of
table~ and suspensiom witl1 a good paJaClhihcy are available.
Tlurd-gellcraQon oral cephalosporins have been used
succes£fully in many community-acquired infections. All of
them (ce podoxime-proxetil. cefixime, ceftibuten and cef-
dinir) h. ve an expanded spectrum of activity and re is nce to
P-1. c mase inactl tion (Figure 1).
Table I shows the Ml 'l\J Vlllues of different oral cepha-
losporins for common p. thogens responsiblc for commuruty-
acqlmed respiratory tract infections in pediatrics.
The lJlain goals in the r:reabnent of community-a quired
respiratory Ir.Ict infcCllons in pediatrics are, for ~'x:lmple. in onn~
media to stc:rilizc rapidly the area to prevent Ouid coUccrion: ud
subsequent hearing problems, in sinusitis to tenlizt: sinus SCI-TenOIlS
to prevent serious complication. and recurrent morbidity. and in
tonmIitis to crndiClte gJ:oup A streptococci to prevent sccondary
complicaoons and to aclucve patient'S comfort.
WHEN PENICILLIN FAILS
Penicillin atld . rnpiollin are still the recommended dru~ of
cboice (or the treatment of bacterial pediatric comlnunity-
acquired infections. PeniciJlin failures will occur and not only
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phel1omel1on 11.1, beel1 ,1 change from ~u. ceptlhility co
IllterJnedlatt: reSIStance (M I < n'1I1f: from aboul 11.1 10 Ju,e
un Icr I (I pt:/I'I1L).
t'"elthele<s tillS developmcnt' of II1lenlledlace re, l~Clnce has
heen , s,Klaleti \\'Ilh de reased \u<n:pc:ib,hCle, co a nUll1hn of
( lher .lI1ohioli \ beslde\ relll iUIIl\ - JloClhly ehe ccph.llmporms
as \ ell a, mat:rohdc\. ecrra :yclll1es, chloramphenicol .1I1t1
mlllelhopnlll-sull~meth()xa7.olt", In th" th'rap)' r min, l1ledia
dnlf.'S Ih;ll may he ronsidercd In tilt' eWIIl ofamox1 tllin failun:
Include Ihe followlI1g IHI: .11110xlcilhn/clavlllanae·, cer.1c1 r,
cdixl1l1e, cdilroXI1J1t' ax.:ul. c:.:~HM:iI, ccfpodoxime-proxeul.
!or,Karhe( Jl1d cdchmr. In several comp.lfatlv" rna Is, dllrtl-
~t'neratlOIl Lt'phal ponl1s OlILt'-datly (cd,liJlir, ctixlme) and
1\\'ll'e-,b1ly were lesled .Ig,\I11S1 ,11J10XI Illinlclavulall,lle ehnce-
daily 1')1, With respeee co r.let'\ of e1illleal C\ICC or 11TlI'r0\·... lTlent
and h;lni:nolo~1C c1earanc.... all the JnJ~ eOl11pMed t:'vor.Jhle
wuh ,llll XlcllIlll/ela\,ulallaet', .md produccd a lowt'r r.Jtc of
.Ii. rrh<:a, An( ther Iml'ro l'lIh,'lll in the ther:lpy, e.~. of OlJl'l
llledi,l, 11Iighe h,' reducing Ihe ,Intihl tl' lI<:a[l1'1cnc pnlOd (with
amoxicil1mlclavul;lIl:lci:) from Iti 10 1-1 days to 7-10 day' with
e<:phalo\ponm. perhaps If ehc rymp.1nic lllembralle 1 illtan and
If Ihere IS no purulent thsch.lrg" .llter:i day'.
LOWER RESPIRATORY TRACT INFECTIONS
There arc sevt'raJ rderellccs In the hler.JCllrc showl11l,\ eh:1I oral
cephail'ponm C.II also be u cd very succcssfitity 111 tilt'
erearmel1l of c<.lmmul1Ity-ac'luired lowN respIratory tr-ace
1I1t''c: eiOll' IIO--12J. It mil. t bt.' taken ll1to a OUIlI Ih,le lher<."
IS no aClIvlty or ccph,lo~porill ag:Jiml ,Ityplcal haClt'na ;1S
myroplasnl.l. chlam el,a and leWollclla. LIlli If th ...se -agenc.s an
be excluded ehe panellC -an he treated successflllly hy lISlllg a
new eephalmp nn in • short course I' 5-7 days, alld mose f
lhem 'an h,' gIVen, as mentioned before, one<: or eWI e Jaily,
whi h of coursc i an JdVanf.1ge f r beltcr compliance.
SHORT COURSE THERAPY
Cephalosponn or the third generaoon, ll1cludlllg cefi:am<:.
have proved to be I" tent agents also tor holt courst: therapy.
In olle of our ,tlldlt.' ercatJl1el1l of patients WIth GA.
pharyngHls was COlll!' red, :dixll1\t' il Illg/kg/day qJ lor 5
days (,,=(,5) vs. pt'nlClllJll V 2110(lt)O JU/kg ud for III ,b S
(II = 6~) re~ult("ll 111 c1inu:al cure rat"s of l-l6,7%, ,md ,)<J.l-l%,
rl'spectivt'l 113J, Cetlxlllle was adnllnl\lcrt'c1 under ~ludy
onclitiom ehal IIIdicalcd that the situation \\,5 controlled and
the pel1J 111111 \\':~s ~I\'ell for the ull II) days.
ormall , how<:ver, patlt:llts lend to SlOp treall11l'nt f
pelll 11111 V afrer 5 or (, dol S or cven \'arhcr. ehus reduclIlg the
acwal efTicaey raet:, A recclll tlldy of 5(100 GAS pharyngm
palll'n~ 111 Gcrmany IIIdi aled no dll1i:ren l' beeween 5-Jay
treamlcnc \ nh ,1 cephalospnnll or a maCToh,le and a 'landard
to-day COII"e ot' pelllcllhn V. There W.IS only onc casc of
rht'Ulllau f"ver In til(' ct'phalosponll/m.acrohdc gr up and
[WO ca eS f ~lol1lel'llloncphriti. in the penlcilhn V group 1141.
In ehc fUl.ure, It may h<: po, sibIl' to re 'ol1ll11end :i-day
trt'allllelll of CAS ph, ryllj:,oic:i" followmg approval from a
Rt'!-rulatory Auehonty. with eirhcr third-~nerati n ep),alo,-
porins or Illacrohdes, It IS al\o worthwhIle to nOle lhal one 4-
day study 111 ;A pll.lryn~t1S p,lOents showt'd rt-solutlon wuh
celill.lme ,11 _.2 cia s .lI1d wuh pClllcllhl1 V al 2,7 da ,aJrhough
11 IS still recolllmended to u t: 5-day treall11cnc. ddmorw
stlld,es ,Lrt' rCl(llIred co Jcfillc opnlllum treallllelle regullt'llS.
SWITCH THERAPY
11<" recenl devl'1oplll<: 11 I III the ITcatment of mfectlol'lS IS
lI11ravcnous sWlcch lhaapy, ThiS h bet'n brought about both
hy the rc em ,IvalIahlilCY 0 oral cphal ~ponns with cxcdlem
activity anJ by lhe pre, ,ure; placed n 11 plClIs co reducc cos
The con "pc of ''''llch lherapy 15 :IS IoU WS: upon ho plCll
adnus ion for a senous LDfectJon the phYSICian prescnbes
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CnlplnC therapy. COIl\l\lIllg of an imr;Ivenous rhlrd-gcnerari n
~ephJJQ)ponn. then .1fcer 1-2 dJY~. tim l~ \wllche I to an oral
thirJ-~encration cephJlosporin foUowing which the patient i
JI charged. 'dix.lllll;- and other Ihinl-gencr.ni 11 cephalo por-
111\ have been proved 10 be potent \witch-Jown agenu for a
Ilulllher of III h~anon\.
CONCLUDING REMARKS
For Ihe trea01lel1l of pharynglLJ\, p~'l1lcllhn V is 011 the drug of
chOice. III the e em chis treatment is unsuccessful, e.g. because
of lack of comphance. oral cephalo. porin can be u. cd. ome
trials of :i-d:lY course, of treatment have demonstrated the
upenonry of cephalo ponns over perucillm V.
Acme DactcnaJ Otlt15 medIa or slJ1usios. often au ed by S.
IlIIfl"Ulllli<lf. H. i"jlum::tI£ r \II. (tllarrllillis. should be treated
wlth moxki.1I111 .IS a first choice. However, iftte. tIl1ellt is not
mcces.~ful or rebpse 0 urs lJlany alternative of ne\
cephalosponns are avallabie.
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